According to a recent LinkedIn post from Freya Biosciences, CEO Colleen Acosta is expected to attend the Bio€quity 2026 conference in Prague from May 4–6. The event is described as a leading forum for life sciences innovators, investors, and strategic partners, positioning it as a venue for business development and investor engagement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights Freya Biosciences’ focus on therapies targeting inflammation and immune dysregulation in women, and it references recently reported positive topline results from a Phase 1 clinical study. While no additional clinical or financial details are provided, visibility at Bio€quity may support future fundraising, partnering activities, and broader investor awareness around the company’s women’s health pipeline.